Мотинорм 2,5 мг/5 мл 30 мл сироп

Ülke: Kırgızistan

Dil: Rusça

Kaynak: Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

Aktif bileşen:

Домперидон

Mevcut itibaren:

Мэдлей Фармасьютикалз Лтд

ATC kodu:

A03FA03

INN (International Adı):

Domperidone

Doz:

2,5 мг/5 мл 30 мл

Farmasötik formu:

сироп

Paketteki üniteler:

№1

Reçete türü:

по рецепту

Tarafından üretildi:

Мэдлей Фармасьютикалз Лтд (Индия)

Terapötik alanı:

Стимулятор моторики ЖКТ

Ürün özeti:

ПЖВЛС: нет

Yetkilendirme tarihi:

2017-04-10

Ürün özellikleri

rrHcTpyKIIuq
rlo MEArrrIr,rHCKoMv
rrPuMEHEHrrro
JIEKAPCTBEHHOIO
CPEACTBA
MOTIIHOPM@
Topronoe
rra3BaHue:
MorzHoplr@
Me44ynapoAHoe
HerrareHToBaHHoe
Ha3BaHrre:
[ouuepu4on
JlerapcrneHHas
Sopnra
Crapon
Onncanue
flpospaunar
cnponoo6pa3Has.
xlrAKocrb
cBerno-KopnqreBoro rlBera c
MrrHo-aHVcoBbrM
BKyCOM.
Cocran
5 ur
npenapara
co,4ep)Kr4r:
Arcmueuoe
6eu4ecm6o:
AoMnepr,rAona
5 rrar;
BcnotwozamerbHbre sel4ecm6a:
KI4cJIora
MoJrorrHa.rr,
cop6uton
(pacreop
He
Kpr.Icrarlnl4sIrpytoqrafics.
70 %
(E
420), rtwlepprH,
caxapo3a,
MeruJrrrapafl{gporcn6eu:oar
(E
218), nponr{nnn{ApoKcrz6engoar
(E
216), rporruneHrJrr{KoJrB,
Kpacvrenb
Xerrufi
3aKar
FCF(E
I I 0), aponrarLr3arop
Mf,Tuo-aHrrconrrfi
,
BoAa
otrHIrIeHHas.
QaprrarcoreparreBTr.rqecKas
rpynna
Cruuyrxropbr
Moropraxn
XKT.
Koa ATX:
A03F A03.
@apuarco.uorrrqecKrre
cnoft
crna
@apuaxodt,Ha\,tuKa.
.{ounepu4ou
-
aHTafoHr.rcr
perlenropoB
AorraMrrHa,
rrpoKr,rHerr.rK.
AeLICTBIIe
o6ycroueno
COqETAHI,IEM
YTBEP)KAAK)
3aprecrnreJrb
ArrpeKTopa
[enaprarvreHTa
JreKapcrBennoro
o6ecne.renus u
lr.en,uqlrncxofi
TexHIrKIl
MnnncrepcTBa
3ApaBooxpaHeHrr
Krrprurscrcofi
nepuQepnuecKoro
llporunopnorHoe
(racrpoxtrnerlrqecKofo)
4eficrnzx
u aHrafoHr.r3Ma
K
perlerrropurM
AoraMr.rna
([2)
s rpurrepuoft
3oue
xeMopeqelrropoB.
[ounepuAou
rroBhrrlaer
roHyc B
Hr.rxHeM
orAene rrrrrrleBoAa,
ynflmaer
aHTpoAyoAeHanbuylo
troABl{x{Hocrb
r4
ycKoprer
o[opoxHeHr4e
xeJryAKa.
flpanrravecKu
He
BII'TSET
HA XENYAOIIHYIO
CEKPEIIUrc.
@apuarcorcuHemuKo.
,{ounepLr4oH
6rrcrpo a6cop6upyercr r.r3
Kr.r[rerrHr.rKa
rrocJle
rrepopaurluoro
[przeMa
HarorrlaK
c
AocrI,IXeHI,IeM
MaKcLIMiIJIbHbD(
yponHefi
B
rrJra3Me
KpoBlr
r{ep$
30-60
M}rHyr. llonzxenHafl
Kr.rcJrorHocrb
xenyAKa
yMeHrrxaer
a6cop6qrro
AoMrrepraAoHa.
BuogocrynHocrb cocraBJlf,er
rrpr{MepHo
15
%. rurnla 3Harrr.rreJrbHo
yi!(eubrrraer
6uoAocryrrnocrb
AoMrrep[Aona.
CnsgrrsaHr.re
c 6emauu KpoBr4
cocraBJrrer
9I-93
%.
llpenapar
rraera6orusnpyerc.a
B
rrer{eHz
nyreM
rI4ApoKcI{nIrpoBaHI'Is
u N-AesanKl{nupoBaHl4.f,,
flpu
uccleAoBaHr4.flx
Naera6onusMa
rrpenapara
in
vitro
c HcrroJlb3oBaHr{eM
AuarHocrlrr